Source:http://linkedlifedata.com/resource/pubmed/id/11948466
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
6
|
pubmed:dateCreated |
2002-4-11
|
pubmed:abstractText |
The prognostic significance of BRCA2 mRNA levels in tumor tissues was studied in sporadic breast cancer patients. BRCA2 mRNA levels were determined by real-time PCR. Histologic grade III tumors showed significantly (p = 0.001) higher BRCA2 mRNA levels (0.828 +/- 0.102 BRCA2/beta-glucuronidase mRNA ratio, mean +/- SE) than histologic grade I and II tumors (0.438 +/- 0.055) and estrogen receptor (ER)-negative tumors (0.773 +/- 0.102) showed a nonsignificant (p = 0.072) trend toward an increase in BRCA2 mRNA levels compared to ER-positive tumors (0.541 +/- 0.079). Other clinicopathologic parameters, such as menopausal status, lymph node status and tumor size, were not significantly associated with BRCA2 mRNA levels. Patients with high BRCA2 mRNA levels showed a significantly (p = 0.006) lower 5-year disease free survival rate (63%) than those with low levels (94%). Lymph node metastases, ER negativity and high histologic grade were also significantly (p < 0.05) associated with poor prognosis. Multivariate analysis revealed that BRCA2 mRNA levels were a significant prognostic factor, being independent of the other conventional prognostic factors. Our results suggest that BRCA2 mRNA levels might serve as a clinically useful prognostic factor in breast cancer patients.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Apr
|
pubmed:issn |
0020-7136
|
pubmed:author | |
pubmed:copyrightInfo |
Copyright 2002 Wiley-Liss, Inc.
|
pubmed:issnType |
Print
|
pubmed:day |
20
|
pubmed:volume |
98
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
879-82
|
pubmed:dateRevised |
2007-7-24
|
pubmed:meshHeading |
pubmed-meshheading:11948466-BRCA2 Protein,
pubmed-meshheading:11948466-Breast Neoplasms,
pubmed-meshheading:11948466-Carcinoma, Ductal, Breast,
pubmed-meshheading:11948466-Carcinoma, Lobular,
pubmed-meshheading:11948466-Disease-Free Survival,
pubmed-meshheading:11948466-Female,
pubmed-meshheading:11948466-Follow-Up Studies,
pubmed-meshheading:11948466-Gene Expression,
pubmed-meshheading:11948466-Humans,
pubmed-meshheading:11948466-Lymphatic Metastasis,
pubmed-meshheading:11948466-Menopause,
pubmed-meshheading:11948466-Neoplasm Invasiveness,
pubmed-meshheading:11948466-Prognosis,
pubmed-meshheading:11948466-RNA, Messenger,
pubmed-meshheading:11948466-RNA, Neoplasm,
pubmed-meshheading:11948466-Receptors, Estrogen,
pubmed-meshheading:11948466-Reverse Transcriptase Polymerase Chain Reaction
|
pubmed:year |
2002
|
pubmed:articleTitle |
High BRCA2 mRNA expression predicts poor prognosis in breast cancer patients.
|
pubmed:affiliation |
Department of Surgical Oncology, Osaka University Medical School, Osaka, Japan.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|